1996 Fiscal Year Final Research Report Summary
Diagnpsis of lung cancer with human monoclonal antibody
| Project/Area Number |
07671488
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
KAWAMURA Masafumi Assistant, Keio University General Thoracic surgery, Surgery, 医学部, 助手 (70169770)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOHNO Mitsutomo Assistant, Keio University General Thoracic surgery, Surgery, 医学部, 助手 (10276272)
NARUKE Masao Assistant, Keio University General Thoracic surgery, Surgery, 医学部, 助手 (30255476)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Keywords | monoclonal antibody / lung cancer |
|---|
| Research Abstract |
A human monoclonal antibody against human lung cancer was prepared to use for cancer treatment and diagnosis.
In 1995, this antibody was labeled with FITC and inspected its specificity for human lung cancer cells by using 20 specimens of human lung cancer tissues resected in the operations. This examination proved it had specific affinity to human squamous cell carcinoma cells and small cell carcinoma cells of the lung. The same result was obtained in the examination using the mince of these cancer tissues. However, this antibody's affinity was insufficient to get well stained cancer tissues. Though some parts of each cancer tissue were certainly stained, even in such portions their degree were not satisfying.
Another study for this monoclonal antibody was tried with the sputa discharged from the patients with lung cencer and inflammatory lung diseases and from healthy voluntiers. The sputa from lung cancer patients had been previously certified to include cancer cells in themselves pathologically. Only the cancer cells contained by sputa from the patients with squamous cell carcinoma were stained by this antibody. This data shows the good specificity of this antibody.
Now it is required to establish a new cell line which can produce more amount of human monoclonal antibody with the stronger affinity for cancer cells. We started to get such a cell lines in 1996.
|
